IRS2 copy number gain, KRAS and BRAF mutation status as predictive biomarkers for response to the IGF-1R/IR inhibitor BMS-754807 in colorectal cancer cell lines

Molecular Cancer Therapeutics

Volumn 14, Issue 2, 2015, Pages 620-630

  Huang, Fei ^a   Chang, Han ^a   Greer, Ann ^a   Hillerman, Stephen ^a   Reeves, Karen A ^a   Hurlburt, Warren ^a   Cogswell, John ^a   Patel, Dharmesh ^a   Qi, Zhenhao ^a   Fairchild, Craig ^a   Ryseck, Rolf Peter ^a   Wong, Tai W ^a   Finckenstein, Friedrich G ^a   Jackson, Jeffrey ^a   Carboni, Joan M ^a  

^a BRISTOL MYERS SQUIBB   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

1 [4 [(5 CYCLOPROPYL 1H PYRAZOL 3 YL)AMINO]PYRROLO[2,1 F][1,2,4]TRIAZIN 2 YL] N (6 FLUORO 3 PYRIDINYL) 2 METHYL 2 PYRROLIDINECARBOXAMIDE; B RAF KINASE; INSULIN RECEPTOR SUBSTRATE 2; K RAS PROTEIN; SOMATOMEDIN C RECEPTOR; BRAF PROTEIN, HUMAN; INSULIN RECEPTOR; INSULIN RECEPTOR SUBSTRATE; IRS2 PROTEIN, HUMAN; KRAS PROTEIN, HUMAN; LIGAND; ONCOPROTEIN; PYRAZOLE DERIVATIVE; RAS PROTEIN; SOMATOMEDIN BINDING PROTEIN 6; TRIAZINE DERIVATIVE; TUMOR MARKER;

ARTICLE; CANCER CELL CULTURE; CELL PROLIFERATION; COLORECTAL CANCER; COPY NUMBER VARIATION; FLUORESCENCE IN SITU HYBRIDIZATION; GENE MUTATION; HUMAN; HUMAN CELL; PRIORITY JOURNAL; PROTEIN EXPRESSION; SINGLE NUCLEOTIDE POLYMORPHISM; TISSUE CULTURE; WESTERN BLOTTING; ANTAGONISTS AND INHIBITORS; BIOLOGICAL MODEL; COLORECTAL TUMOR; DRUG EFFECTS; GENE AMPLIFICATION; GENE DOSAGE; GENETICS; METABOLISM; MUTATION; NUCLEOTIDE SEQUENCE; PHOSPHORYLATION; TUMOR CELL LINE;

BLOTTING, WESTERN; CELL LINE, TUMOR; COLORECTAL NEOPLASMS; DNA COPY NUMBER VARIATIONS; DNA MUTATIONAL ANALYSIS; GENE AMPLIFICATION; GENE DOSAGE; HUMANS; INSULIN RECEPTOR SUBSTRATE PROTEINS; INSULIN-LIKE GROWTH FACTOR BINDING PROTEIN 6; LIGANDS; MODELS, BIOLOGICAL; MUTATION; PHOSPHORYLATION; PROTO-ONCOGENE PROTEINS; PROTO-ONCOGENE PROTEINS B-RAF; PYRAZOLES; RAS PROTEINS; RECEPTOR, IGF TYPE 1; RECEPTOR, INSULIN; TRIAZINES; TUMOR MARKERS, BIOLOGICAL;

EID: 84923385676     PISSN: 15357163     EISSN: 15388514     Source Type: Journal    
DOI: 10.1158/1535-7163.MCT-14-0794-T     Document Type: Article

References (42)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer Statistics 2010. CA Cancer J Clin 2010;60:277-300.
2. Samani AA, Yakar S, LeRoith D, Brodt P. The role of the IGF system in cancer growth and metastasis: overview and recent insights. Endocr Rev 2007;28:20-47.
3. Frasca F, Pandini G, Sciacca L, Pezzino V, Squatrito S, Belfiore A, et al. The role of insulin receptors and IGF-I receptors in cancer and other diseases. Arch Physiol Biochem 2008;114:23-37.
4. Donovan EA, Kummar S. Role of insulin-like growth factor-1R system in colorectal carcinogenesis. Crit Rev Oncol Hematol 2008;66:91-8.
5. Ewing GP, Goff LW. The insulin-like growth factor signaling pathway as a target for treatment of colorectal carcinoma. Clin Colorectal Cancer 2010;9:219-23.
6. Gao J, Chang YS, Jallal B, Viner J. Targeting the insulin-like growth factor axis for the development of novel therapeutics in oncology. Cancer Res 2012;72:3-12
7. Gualberto A, Pollak M. Emerging role of insulin-like growth factor receptor inhibitors in oncology: early clinical trial results and future directions. Oncogene 2009;28:3009-21.
8. Weroha SJ, Haluska P. IGF-1 receptor inhibitors in clinical trials-Early lessons. J. Mamm Gland Biol Neoplasia 2008;13:471-83.
9. Pollak M. The insulin and insulin-like growth factor receptor family in neoplasia: an update. Nat Rev Cancer 2012;12:159-69.
10. Belfiore A, Frasca F, Pandini G, Sciacca L, Vigneri R. Insulin receptor isoforms and insulin receptor/insulin-like growth factor receptor hybrids in physiology and disease. Endocr Rev 2009;30:586-623
11. Zhang H, Pelzer AM, Kiang DT, Yee D. Down-regulation of type I insulin-like growth factor receptor increases sensitivity of breast cancer cells to insulin. Cancer Res 2007;67:391-7
12. Ulanet DB, Ludwig DL, Kahn CR, Hanahan D. Insulin receptor functionally enhances multistage tumor progression and conveys intrinsic resistance to IGF-1R targeted therapy. Proc Natl Acad Sci U S A 2010;107:10791-8
13. Buck E, Gokhale PC, Koujak S, Brown E, Eyzaguirre A, Tao N, et al. Compensatory insulin receptor (IR) activation on inhibition of insulin-like growth factor-1 receptor (IGF-1R): rationale for cotargeting IGF-1R and IR in cancer. Mol Cancer Ther 2010;9:2652-64
14. Brierley GV, Macaulay SL, Forbes BE, Wallace JC, Cosgrove LJ, Macaulay VM. Silencing of the insulin receptor isoform A favors formation of type 1 insulin-like growth factor receptor (IGF-IR) homodimers and enhances ligand-induced IGF-IR activation and viability of human colon carcinoma cells. Endocrinology 2010;151:1418-27.
15. Huang F, Greer A, Hurlburt W, Han X, Hafezi R, Wittenberg GM, et al. The mechanisms of differential sensitivity to an insulin-like growth factor-1 receptor inhibitor (BMS-536924) and rationale for combining with EGFR/HER2 inhibitors. Cancer Res 2009;69:161-70.
16. Litzenburger BC, Creighton CJ, Tsimelzon A, Chan BT, Hilsenbeck SG, Wang T, et al. High IGF-IR activity in triple-negative breast cancer cell lines and tumorgrafts correlates with sensitivity to anti-IGF-IR therapy. Clin Cancer Res 2011;17:2314-27.
17. Pitts TM, Tan AK, Kulikowski GN, Tentler JJ, Brown AM, Flanigan SA, et al. Development of an integrated genomic classifier for a novel agent in colorectal cancer: approach to individualized therapy in early development. Clin Cancer Res 2010;16:3193-204.
18. Gualberto A, Hixon ML, Karp DD, Li D, Green S, Dolled-Filhart M, et al. Pre-treatment levels of circulating free IGF-1 identify NSCLC patients who derive clinical bene fit from figitumumab. Br J Cancer 2011;104:68-74.
19. Pavlicek A, Lira ME, Lee NV, Ching KA, Ye J, Cao J, et al. Molecular predictors of sensitivity to the insulin-like growth factor 1 receptor inhibitor Figitumumab (CP-751,871). Mol Cancer Ther 2013;12:2929-39.
20. Tognon CE, Sorensen PH. Targeting the insulin-like growth factor 1 receptor (IGF1R) signaling pathway for cancer therapy. Expert Opin Ther Targets 2012;16:33-48.
21. Yee D. Insulin-like growth factor receptor inhibitors: baby or the bath-water? J Natl Cancer Inst 2012;104:975-81.
22. Carboni JC, Wittman M, Yang Z, Lee F, Greer A, Hurlburt W, et al. BMS-754807, a small molecule inhibitor of insulin-like growth factor-1R/IR. Mol Cancer Ther 2009;8:3341-9.
23. Huang F, Reeves K, Han X, Fairchild C, Platero S, Wong TW, et al. Identification of candidate molecular markers predicting sensitivity in solid tumors to dasatinib: rationale for patient selection. Cancer Res 2007;67:2266-38.
24. Forbes SA, Tang G, Bindal N, Bamford S, Dawson E, Cole C, et al. COSMIC (the Catalogue of Somatic Mutations in Cancer): a resource to investigate acquired mutations in human cancer. Nucleic Acids Res 2010;38(Database issue):D652-7.
25. Huang F, Hurlburt W, Greer A, Reeves KA, Hillerman S, Chang H, et al. Differentialmechanisms of acquired resistance to insulin-like growth factor-I receptor antibody therapy or to a small-molecule inhibitor, BMS-754807, in a human rhabdomyosarcoma model. Cancer Res 2010;70:7221-31.
26. Clemens PL, Park JS, Cohen MB, Zhang D, Huang F, Hodsman P, et al. BMS-754807, an oral dual IGF-1R/IR inhibitor: first-in-human single-dose study of safety, tolerability, pharmacokinetics, and pharmacodynamics in healthy subjects. Mol Cancer Ther 2009;8(12 Suppl):A101.
27. Desai J, Solomon B, Davis ID, Lipton LR, Hicks R, Scott AM, et al. Phase I dose-escalation study of daily BMS-754807, an oral, dual IGF-1R/insulin receptor (IR) inhibitor in subjects with solid tumors. ASCO Meeting Abstracts Jun 14, 2010:3104.
28. Reynolds JM, Lloyd DB, Bentivegna SC, Seymour AB, Borzillo GV, Gualberto A. Insulin-like growth factor 1 receptor mutants are inhibited by figitumumab (CP-751, 871) in vitro. Mol Cancer Ther 2009;8(12 Suppl): B119.
29. Reid JF, Gariboldi M, Sokolova V, Capobianco P, Lampis A, Perrone F, et al. Integrative approach for prioritizing cancer genes in sporadic colon cancer. Genes Chromosomes Cancer 2009;48:953-62.
30. Barretina J, Caponigro G, Stransky N, Venkatesan K, Margolin AA, Kim S, et al. The Cancer Cell Line Encyclopedia enables predictive modelling of anticancer drug sensitivity. Nature 2012;483:603-7.
31. Garnett MJ, Edelman EJ, Heidorn SJ, Greenman CD, Dastur A, Lau KW, et al. Systematic identification of genomic markers of drug sensitivity in cancer cells. Nature 2012;483:570-5.
32. Bohanes P, LaBonte MJ, Winder T, Lenz HJ. Predictive molecular classifiers in colorectal cancer. Semin Oncol 2011;38:576-87.
33. De Roock W, De Vriendt V, Normanno N, Ciardiello F, Tejpar S. KRAS, BRAF, PIK3CA, and PTEN mutations: implications for targeted therapies in metastatic colorectal cancer. Lancet Oncol 2011;12:594-603.
34. ERBITUX® (cetuximab) [package insert]. Branchburg (NJ) and Princeton (NJ): ImClone LLC and Bristol-Myers Squibb Company; 2012.
35. De Roock W, Jonker DJ, Di Nicolantonio F, Sartore-Bianchi A, Tu D, Siena S, et al. Association of KRAS p.G13D mutation with outcome in patients with chemotherapy-refractory metastatic colorectal cancer treated with cetuximab. JAMA 2010;304:1812-20.
36. Guerrero S, Casanova I, Farré L, Mazo A, Capellà G, Mangues R. K-ras codon 12 mutation induces higher level of resistance to apoptosis and predisposition to anchorage-independent growth than codon 13 mutation or proto-oncogene overexpression. Cancer Res 2000;60:6750-6.
37. van der Veeken J, Oliveira S, Schiffelers RM, Storm G, van Bergen En Henegouwen PM, Roovers RC. Crosstalk between epidermal growth factor receptor- and insulin-like growth factor-1 receptor signaling: implications for cancer therapy. Curr Cancer Drug Targets 2009;9:748-60
38. Ebi H, Corcoran RB, Singh A, Chen Z, Song Y, Lifshits E, et al., Receptor tyrosine kinases exert dominant control over PI3K signaling in human KRAS mutant colorectal cancers. J Clin Invest 2011;121:4311-21.
39. Samuels Y, Wang Z, Bardelli A, Silliman N, Ptak J, Szabo S, et al. High frequency of mutations of the PIK3CA gene in human cancers. Science 2004;304:554.
40. Nosho K, Kawasaki T, Ohnishi M, Suemoto Y, Kirkner GJ, Zepf D, et al. PIK3CA mutation in colorectal cancer: relationship with genetic and epigenetic alterations. Neoplasia 2008;10:534-41.
41. Molina-Arcas M, Hancock DC, Sheridan C, Kumar MS, Downward J. Coordinate direct input of both KRAS and IGF1 receptor to activation of PI3 kinase in KRAS-mutant lung cancer. Cancer Discov 2013;3:548-63.
42. Hou X, Huang F, Macedo LF, Harrington SC, Reeves KA, Greer A, et al. Dual IGF-1R/InsR inhibitor BMS-754807 synergizes with hormonal agents in treatment of estrogen-dependent breast cancer. Cancer Res 2011;71:7597-607.